EXPERT REVIEW OF ANTICANCER THERAPY

Edit Your Profile

EXPERT REVIEW OF ANTICANCER THERAPY Journal

publication venue for

Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care? 2021
Immunotherapy: Is a minor god yet in the pantheon of treatments for lung cancer? 2014
Cognitive function testing in adult brain tumor trials: lessons from a comprehensive review 2012
Epidermal growth factor vaccine in non-small-cell lung cancer 2012
Targeting the Met pathway in lung cancer 2012
Active immunotherapy for non-small-cell lung cancer: Moving toward a reality 2011
Development of targeted therapy for squamous cell carcinomas of the head and neck 2011
EGF receptor in lung cancer: A successful story of targeted therapy 2010
Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC 2010
Nasopharyngeal carcinoma: Alternative treatment options after disease progression 2010
Controversies in the management of stage IIIA non-small-cell lung cancer 2008
Targeting important pathways in head and neck cancer: From the bench to the clinic 2008
New targets for non-small-cell lung cancer therapy 2007
Motexafin gadolinium: a novel radiosensitizer for brain tumors 2007
Induction chemotherapy in the management of squamous cell carcinoma of the head and neck 2006
Clinical trials targeting lung cancer with active immunotherapy: The scope of vaccines 2005
DNA methylation: Its role in lung carcinogenesis and therapeutic implications 2005
Motexafin gadolinium: A clinical review of a novel radioenhancer for brain tumors 2004

category

ONCOLOGY Category

International Standard Serial Number (ISSN)

1473-7140

Electronic International Standard Serial Number (EISSN)

1744-8328

journal abbreviation

EXPERT REV ANTICANC